Biotech

All Articles

Pfizer takes $230M hit after axing failed DMD genetics treatment

.Pfizer's stage 3 Duchenne muscular dystrophy (DMD) gene therapy breakdown has actually gone a $230 ...

AC Immune sees 'spots' potential in Alzheimer's drug data

.After more than two decades of service neurodegenerative ailments, Swiss biotech AC Immune cases it...

GSK goes down ph. 2 HPV vaccine over shortage of best-in-class prospective

.GSK has broken up a stage 2 individual papillomavirus (HPV) vaccine coming from its pipeline after ...

OS Treatments refiles $6M IPO to fund HER2 drug, preclinical ADCs

.Operating system Therapies will definitely list on the NYSE American inventory swap this morning vi...

ALX's waning CD47 reaction price sends sell spiraling down

.ALX Oncology's period 2 stomach cancer cells reaction price has actually deteriorated. After observ...

Ionis axes eye condition coming from targets of Roche-partnered prospect after records dissatisfy

.An Additional of Ionis Pharmaceuticals' vital midphase readouts has actually disappointed expectati...

Biogen's CEO stated no high-risk sell 2023. He prepares to be daring

.While Biogen's pharma peers are seeking for late-stage resources along with little risk, CEO Chris ...

Instil refills pipeline in $2B biobucks take care of ImmunOnco

.Instil Biography has actually been actually a biotech searching for a pipe after it scrapped its ow...

Biogen walks away from Denali Alzheimer's collab

.Biogen has handed back liberties to a very early Alzheimer's condition plan to Denali Rehabs, leavi...

Takeda touches brand new head people oncology service-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of significant leadership hirings, shootings and...